オプションチェーンは、Telomir Pharmaceuticalsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Telomir Pharmaceuticalsの市場センチメントを評価します。.

Telomir Pharmaceuticals (NASDAQ:TELO) 株価情報, オプションチェーン

Telomir Pharmaceuticals

Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.

Telomir Pharmaceuticals, Inc. - Common Stock

Telomir Pharmaceuticals Inc

TELO GENOMICS CORP by Telo Genomics Corp.

Telo Genomics Corp

Telos - United States Dollar

Telos Corp

Syra Health Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>), a healthcare technology company dedicated to powering better health through innovative technology products and services, announced today a one-year, $660,000 Population Health contract extension with a national healthcare organization. This agreement, combined with the previous year's agreement, brings the total contract value up to $1.32 million.

News

Contracts

SYRA

Syra Health Secures 1-Year $660,000 Population Health Contract Extension With A National Healthcare Organization

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>B of A Securities analyst Brad Sills downgraded the rating for UiPath Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) from Neutral to Underperform and lowered the price target from $18 to $10. UiPath shares closed at $11.83 on Wednesday. <a href="https://www.benzinga.com/quote/path/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Ryan Kenny downgraded Moelis &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MC#NYSE">MC</a>) from Overweight to Underweight and lowered the price target from $100 to $70. Moelis shares closed at $60.09 on Wednesday. <a href="https://www.benzinga.com/quote/mc/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham analyst David Saxon downgraded the rating for DENTSPLY SIRONA Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) from Buy to Hold. Dentsply Sirona shares closed at $15.33 on Wednesday. <a href="https://www.benzinga.com/quote/XRAY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities analyst Ki Bin Kim downgraded Federal Realty Investment Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRT#NYSE">FRT</a>) from Buy to Hold and lowered the price target from $114 to $105. Federal Realty Investment shares closed at $97.12 on Wednesday. <a href="https://www.benzinga.com/quote/FRT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham analyst David Saxon downgraded the rating for ZimVie Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZIMV#NASDAQ">ZIMV</a>) from Buy to Hold. ZimVie shares closed at $12.65 on Wednesday. <a href="https://www.benzinga.com/quote/ZIMV/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying PATH stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="595" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13080714/image-103-1024x595.png" alt="" class="wp-image-822803" style="width:585px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13080714/image-103-1024x595.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13080714/image-103-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13080714/image-103-768x446.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13080714/image-103.png 1121w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44295828/adobe-intel-and-3-stocks-to-watch-heading-into-thursday">Adobe, Intel And 3 Stocks To Watch Heading Into Thursday</a></li>
</ul>

Downgrades

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

PATH

XRAY

ZIMV

This UiPath Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday

WIIM

FAMI

Farmmi shares are trading lower after the company announced a 1-for-12 share consolidation to regain Nasdaq compliance.

Barclays analyst Lauren Lieberman upgrades Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) from Underweight to Equal-Weight and raises the price target from $56 to $62.

Upgrades

Price Target

Barclays Upgrades Molson Coors Beverage to Equal-Weight, Raises Price Target to $62

IPDN

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/03/12/final-trades-nvidia-taiwan-semi-amazon-and-the-iefa.html">Halftime Report Final Trades</a>,&#8221; Rob Sechan of NewEdge Wealth said he is a <a href="https://www.benzinga.com/quote/NVDA/analyst-ratings">buyer of NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).</a>
Supporting his view, on Feb. 27 Cantor Fitzgerald analyst Matthew Prisco reiterated Nvidia with an Overweight rating and maintained a $200 price target.
Stephen Weiss of Short Hills Capital Partners said he likes Taiwan Semiconductor Manufacturing Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>). The company&#8217;s shares gained on Wednesday following a report suggesting it pitched a joint venture with several chip designers to operate Intel&#8217;s factories.
 Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Shannon Saccocia of NB Private Wealth named iShares Core MSCI EAFE ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IEFA#NASDAQ">IEFA</a>) as her final trade.
Joseph M. Terranova of Virtus Investment Partners picked Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>).
Amazon.com cloud unit Amazon Web Services looks to invest $8.2 billion in India's western state of Maharashtra over the next few years, Reuters cited the Indian information technology minister Ashwini Vaishnaw on March 3.
Price Action:
<ul>
<li>Nvidia shares gained 6.4% to close at $115.74 on Wednesday.</li>
<li>Taiwan Semiconductor rose 3.6% to settle at $177.17 during Wednesday's session.</li>
<li>iShares Core MSCI EAFE ETF gained 0.7% on Wednesday.</li>
<li>Amazon.com shares gained 1.2% to close at $198.89 on Wednesday.</li>
</ul>
Check This Out:
<ul>
<li><a href="https://www.benzinga.com/25/03/44274110/top-2-industrials-stocks-that-may-collapse-in-march"> Top 2 Industrials Stocks That May Collapse In March</a></li>
</ul>
Photo: Shutterstock

Media

AMZN

IEFA

NVDA

Amazon, Nvidia, Taiwan Semiconductor And More On CNBC's 'Final Trades'

Barclays analyst Adrienne Yih downgrades American Eagle Outfitters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) from Equal-Weight to Underweight and lowers the price target from $17 to $10.

Barclays Downgrades American Eagle Outfitters to Underweight, Lowers Price Target to $10

Build-A-Bear Workshop, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBW#NYSE">BBW</a>) shares are trading higher in the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44298444/build-a-bear-workshop-reports-record-breaking-fourth-quarter-and-fiscal-2024-results-increases-qua" rel="noreferrer noopener">premarket session on Thursday.</a>
The company reported fourth-quarter adjusted earnings per share of $1.59, beating the street view of $1.50.
Quarterly sales of $150.45 million (+0.8% year over year) outpaced the analyst consensus estimate of $147.53 million. Excluding the extra week of operations in the fourth quarter of 2023, revenues increased 5.7%.
Net retail sales were $139.5 million, down 0.5% on a GAAP basis. Excluding the extra week of operations in the fourth quarter of 2023, net retail sales increased 4.7%.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/25/03/44293798/elon-musk-expects-tesla-output-to-double-over-next-couple-of-years-but-gene-munster-predicts-number-to-drop-before-a-surge-in-2026" rel="noreferrer noopener">Elon Musk Expects Tesla Output To Double Over Next Couple Of Years, But Gene Munster Predicts Number To Drop Before A Surge In 2026</a>
&#8220;This year, Build-A-Bear launched 64 net new retail units, the majority of which were asset-light partner-operated locations, increasing its international presence to more than 25 countries,&#8221; commented Sharon Price John, President and Chief Executive Officer of Build-A-Bear Workshop.
At the end of the fiscal year, cash and cash equivalents were $27.8 million, down $16.6 million from $44.3 million last year.
This decrease was due to higher inventory investment to offset potential tariffs and an increase in accounts receivable from growth in the Commercial segment.
For the quarter, the company had net new unit growth of 24 global experience locations, comprised of six corporately-managed locations, 15 partner-operated locations, and three franchise locations.
Dividend: As announced on March 12, the company declared a quarterly dividend of $0.22 per share, <a target="_blank" href="https://www.benzinga.com//node/44288650" rel="noreferrer noopener">reflecting a 10% increase.</a>
Outlook: For fiscal 2025, the company expects mid-single-digit percentage growth in total revenue. Pre-tax income may either decline or grow slightly due to over $10 million in additional costs, including tariff impacts and <a href="https://www.benzinga.com/calendars/guidance">higher medical and labor expenses.</a>
The company also anticipates net new unit growth of at least 50 locations through corporate, partner, and franchise models.
In a separate press release, Build-A-Bear Workshop has announced plans to launch a new retail experience at one of the largest tourist destinations in the U.S., Orlando, Florida, in the first half of 2026. Construction is set to <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44297806/build-a-bear-workshop-announces-plans-for-multi-level-retail-experience-in-orlando-florida" rel="noreferrer noopener">begin later this year.</a>
Price Action: BBW shares are trading higher by 1.41% to $36.00 premarket at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/03/44267822/palantir-executive-pushes-pentagon-to-adopt-software-first-approach-noting-us-allocates-less-than-1-of-defense-budget-to-modern-battlefield" target="_blank" rel="noreferrer noopener">Palantir Calls For ‘Software-First Approach' As Pentagon Spends Under 1% On Modern Warfare</a></li>
</ul>
Image via Shutterstock.

Earnings

Equities

Guidance

Movers

General

Build-A-Bear Workshop Q4 Earnings: Sales And EPS Beat, New Retail Launches And More

U.S. producer prices unexpectedly stagnated in February, while core inflation posted a rare contraction, reinforcing hopes that cost pressures may be easing despite lingering <a href="https://www.benzinga.com/topic/inflation">concerns over trade tariffs.</a>
The Producer Price Index (PPI) remained flat on a monthly basis in February, a sharp deceleration from January's upwardly revised 0.6% gain and below expectations of a 0.3% increase. 
Core PPI, which excludes food and energy, fell 0.1% in February, marking its first monthly decline since July 2024. This came after January's figure was revised higher to a 0.5% gain. 
On a year-over-year basis, headline producer inflation eased to 3.2%, down from January's upwardly revised 3.7%, while core PPI slowed to 3.4%, from a revised 3.8% in the previous month.
The weaker-than-expected producer inflation report follows Friday's consumer price index data, which also came in softer than anticipated, strengthening the case for Federal Reserve rate cuts later this year.
<h3 class="wp-block-heading">Price Drivers: Food Jumps, Services Fall</h3>
The muted headline figure masked significant divergences across categories. Food prices surged 1.7%, largely driven by an extraordinary 53.6% spike in egg prices. 
Other contributors to the increase included pork, fresh and dry vegetables, electric power, tobacco products, and carbon steel scrap.
Yet, gasoline prices fell 4.7%, exerting downward pressure on the overall index.
Meanwhile, the index for final demand services declined 0.2%, the steepest drop since July 2024, suggesting cooling inflationary pressures in service-related sectors.
<h3 class="wp-block-heading">Market Reactions</h3>
<ul>
<li>U.S. dollar: The dollar strengthened despite the softer PPI report, with the U.S. dollar index, tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), rising 0.4%.</li>
<li>Treasury yields: The 10-year U.S. Treasury yield increased 2 basis points to 4.33% as markets reassessed inflation risks.</li>
<li>Stock market: Selling pressure on equities resumed after a brief rebound on Wednesday. Futures on major U.S. indices recorded losses in the premarket trading, with S&amp;P 500 futures down 0.2% at 8:39 a.m. ET.</li>
<li>On Wednesday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) closed at $558.87, up 0.5% but still hovering near its lowest levels in seven months and about 3% below its 200-day moving average.</li>
</ul>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44298732/nvidia-valuation-drops-after-2025-rout-ai-chipmakers-price-declines-41-from-its-peak-when-chatgpt-was-launched">Nvidia Valuation Drops After 2025 Rout: Chipmaker&#8217;s Price Declines 41% From Its Peak When ChatGPT Was Launched</a></li>
</ul>
Photo: Shutterstock

Macro Economic Events

Broad U.S. Equity ETFs

Currency ETFs

Econ #s

Economics

ETFs

PowerShares DB US Dollar Index Bullish Fund

US Producer Inflation Stalls In February As Services Costs Drop, Eggs Price Skyrockets

JP Morgan analyst Arun Jayaram upgrades Range Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>) from Underweight to Neutral and raises the price target from $43 to $45.

JP Morgan Upgrades Range Resources to Neutral, Raises Price Target to $45

Urgent.ly shares are trading lower after the company announced a 1-for-12 reverse stock split.

CCLD

CareCloud shares are trading higher after the company reported better-than-expected Q4 financial results.

Crown Castle Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) will release its fourth-quarter financial results, after the closing <a href="https://www.benzinga.com/quote/CCI/earnings">bell, on Thursday, March 13</a>.
Analysts expect the company to report quarterly earnings at 40 cents per share. That&#8217;s down from 86 cents per share in the year-ago period. Crown Castle projects quarterly revenue of $1.64 billion. It generated $1.67 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Feb. 13, Citigroup analyst Michael Rollins maintained Crown Castle with a Buy rating and lowered the price target from $128 to $106.
With the recent buzz around Crown Castle, some investors may be eyeing potential gains from the company's dividends too. As of now, Crown Castle offers an annual dividend yield of 6.57%, which is a quarterly dividend amount of $1.56 cents per share ($6.26 a year). &nbsp;
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $91,288 or around 958 shares. For a more modest $100 per month or $1,200 per year, you would need $18,296 or around 192 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($6.26 in this case). So, $6,000 / $6.26 = 958 ($500 per month), and $1,200 / $6.26 = 192 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
CCI Price Action: Shares of Crown Castle fell 2.4% to close at $95.29 on Wednesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44274110/top-2-industrials-stocks-that-may-collapse-in-march">Top 2 Industrials Stocks That May Collapse In March</a></li>
</ul>
Image: Shutterstock

Long Ideas

How To Earn $500 A Month From Crown Castle Stock Ahead Of Q4 Earnings

On Thursday, Janover Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JNVR#NASDAQ">JNVR</a>) announced <a target="_blank" href="https://www.benzinga.com/topic/commercial-real-estate" rel="noreferrer noopener">its financial results</a> for the fourth quarter ended December 31, 2024.
The fourth-quarter revenue of the commercial property financing solutions provider grew by 80% year-on-year to $0.63 million.
Platform fees increased 39% to $0.44 million.
Also Read: <a target="_blank" href="https://www.benzinga.com//node/43094784" rel="noreferrer noopener">EXCLUSIVE: Janover Clocks 190% ARR Growth In 2024 Thanks To AI-Powered SaaS Platform</a>
Subscription revenue grew 488% to $0.19 million, while the Annual recurring revenue (ARR) rose 194% to $0.81 million.
Net loss declined 59% to $0.49 million. The quarter&#8217;s net loss reduction was primarily due to significant cost-cutting across the organization, one-time IPO-related expenses, and stock issuances for services in the prior year.
Operating cash flow improved by 73% during the quarter.
CEO Blake Janover attributed the quarterly results to the 488% SaaS subscription revenue growth, which implies 14 times growth for the entire year.
It marked the company&#8217;s fourth consecutive quarter of sequential revenue growth, with net income and subscription revenue improving over the past four quarters.
Price Action: JNVR stock closed higher by 1.82% at $4.47 Wednesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/03/44281974/alibaba-grab-tencent-meituan-gear-up-for-growth-as-china-bets-on-services-to-revive-economy" target="_blank" rel="noreferrer noopener">Alibaba, Grab, Tencent, Meituan Gear Up For Growth As China Bets On Services To Revive Economy</a></li>
</ul>

Market-Moving Exclusives

Exclusives

JNVR

EXCLUSIVE: Janover Clocks 80% Q4 Revenue Growth, 488% Surge In Subscription Revenue

JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) CEO Jamie Dimon has been a big proponent of return-to-office, in an effort to get employees back from <a href="https://www.benzinga.com/topic/remote-work">past remote jobs.</a>
Recent comments show Dimon hasn't changed his stance about believing that workers should be in office settings.
What Happened: Banking veteran Dimon believes remote work should end and is something that "doesn't work in our business," doubling down on his efforts to get workers to<a href="https://www.benzinga.com/markets/equities/25/02/43757032/jamie-dimon-goes-off-on-return-to-office-critics-you-dont-have-to-work-at-jpmorgan"> return to the office.</a>
Dimon's comments came while speaking to students at Stanford University's Graduate School of Business. The banking executive said those frustrated with return-to-office policies are "the people in the middle," like corporate workers, as reported by the New York Post.
"If you work in a restaurant, you've got to be in. You all may not know this, but 60% of Americans worked the whole time," Dimon said.
His comments recalled the COVID-19 pandemic that shut down many businesses and sectors and saw a boom in remote work.
"Where did you get your Amazon packages from? Your beef, your meat, your vodka? Where did you get the diapers from?"
Dimon said several industries had employees working during the pandemic and remote work wasn't a thing for them.
"You got UPS and FedEx and manufacturers and agriculture and hospitals and cities and schools and nurses and sanitation and firemen and military. They all worked."
Read Also:<a href="https://www.benzinga.com/news/24/04/38149277/jamie-dimon-equates-ai-to-printing-press-steam-engine-consequences-will-be-extraordinary"> Jamie Dimon Equates AI To Printing Press, Steam Engine: &#8216;Consequences Will Be Extraordinary&#8217;</a>
Why It's Important: The banking executive said he defends the rights of people who choose to quit over return-to-office policies, but not those telling him what JPMorgan should do.
"You have a free market. You can do one thing, I can do another. That's what's called a free market."
Dimon said there are cases where remote work is still a possibility.
"We put virtual call centers in Baltimore and Detroit. We did it to see if they'd be effective. They're highly effective. They work from home. They're mostly minorities. That's why we did it," Dimon said.
Dimon&#8217;s comments come after he was critical of people against JPMorgan's return-to-office policies last month. He said workers back in the office is good with younger people being left behind socially and professionally.
Dimon also commented about the ability to communicate between in-person and remote workers.
"It doesn't work in our business. And for culture, you talk about culture, it's impossible to do culture."
Dimon's comments come as the national government is also pushing for return-to-office policies under Donald Trump and Elon Musk&#8217;s orders.
New <a href="https://x.com/Placer_ai/status/1899883071492456883">data </a>from Placer.ai shows which cities in the technology sector are leading in return-to-work policies. San Francisco is at 47.5% and outperforming Chicago (48.5%) for the first time in visit gaps since data has been tracked in the post-pandemic office recovery.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/education/25/03/44209404/if-you-invested-1000-in-jpmorgan-chase-stock-when-jamie-dimon-became-the-ceo-heres-how-much-youd-have-today">If You Invested $1,000 In JPMorgan Chase Stock When Jamie Dimon Became The CEO, Here&#8217;s How Much You&#8217;d Have Today</a></li>
</ul>
Photo: Benzinga

Jamie Dimon Doubles Down On Work From Home Criticism: 'Where Did You Get Your Amazon Packages?'

Janover Inc. Q4 Total Revenue $628,881, Up 80% YoY;  Annual Recurring Revenue $811,884, Up 194% YoY

Susquehanna analyst Charles Minervino maintains Virgin Galactic Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NYSE">SPCE</a>) with a Neutral and lowers the price target from $4 to $3.25.

SPCE

Susquehanna Maintains Neutral on Virgin Galactic Hldgs, Lowers Price Target to $3.25

CRVO

CervoMed shares are trading higher after Chardan Capital upgraded its rating on the stock from Neutral to Buy.

LUCK

Lucky Strike shares are trading higher. The company reported Q2 financial results.

Susquehanna analyst Shyam Patil maintains SentinelOne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) with a Positive and lowers the price target from $30 to $25.

Susquehanna Maintains Positive on SentinelOne, Lowers Price Target to $25

Press Releases

Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1

Offerings

Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price

Telomir Pharmaceuticals Secures $1 Million At $7 Per Share In No-Warrant, Restricted Stock Deal, Underscoring Investor Confidence With A 20% Premium Valuation

Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease

Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging)

Telomir Pharmaceuticals Announces Breakthrough Results With Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as a Treatment for Avian Influenza (Bird Flu) and Other Viruses

Telomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines, Advancing Potential Treatment for Age-Related Macular Degeneration (AMD)

Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market

Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines

TELO

Aardvark Therapeutics, Inc. - Common Stock

Aardvark Therapeutics

Aclaris Therapeutics, Inc. - Common Stock

Aclaris Therapeutics

Alumis

Alto Neuroscience

Assertio Holdings

Atea Pharmaceuticals, Inc. - common stock

Atea Pharmaceuticals

Bioage Labs

Biote

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland

Contineum Therapeutics, Inc. - Common stock

Contineum Therapeutics

Journey Medical Corporation - Common Stock

Journey Medical

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics

Ikena Oncology

Milestone Pharmaceuticals Inc. - Common Shares

Milestone Pharmaceuticals

Nektar Therapeutics

Neumora Therapeutics, Inc. - Common Stock

Neumora Therapeutics

Nutriband

Oramed Pharmaceuticals Inc. - Common Stock

Oramed Pharmaceuticals

Pliant Therapeutics

Cassava Sciences

scPharmaceuticals

Third Harmonic Bio

Veru

Ventyx Biosciences

Zhengye Biotechnology Holding Limited - Ordinary Shares

Comments

Telomir Pharmaceuticals

Telomir Pharmaceuticals (TELO) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル